We evaluated the diffusion of ciprofloxacin into the cerebrospinal fluid (CSF) 216, 1985). These in vitro and in vivo studies led to the current evaluation of the penetration of ciprofloxacin into the CSF of patients with bacterial meningitis who were undergoing concurrent treatment with conventional antibiotics.
Ciprofloxacin has an extremely broad range of antibacterial activity, including most organisms responsible for purulent meningitis, except Streptococcus pneumoniae (1) . In a recent study it has been demonstrated that ciprofloxacin diffuses into the cerebrospinal fluid (CSF) of rabbits with experimental ampicillin-resistant Haemophilus influenzae meningitis. Moreover, it was rapidly bactericidal in this model (M. W. Sobiesky and W. M. Scheld, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 216, 1985) . These in vitro and in vivo studies led to the current evaluation of the penetration of ciprofloxacin into the CSF of patients with bacterial meningitis who were undergoing concurrent treatment with conventional antibiotics.
(This work was presented in part at the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., October 1986.) MATERIALS spectrofluorometric detector (Shimadzu RF 530) was used to measure the ciprofloxacin at an excitation/emission wavelength pair of 276/441 nm. The peak areas were measured on a Delsi Icap 50 recorder. The degassed mobile phase consisted of a mixture of methanol (RP Normapur; Prolabo) and Pic A (tetrabutyl-ammonium phosphate; Waters) acidified to pHI 3.00 with orthophosphoric acid, monitored by a pH meter. The proportions of the methanol-Pic A mixture were, respectively, 20 and 80% for the plasma levels and 18 and 82% for the CSF levels. The flow rate was 1.5 ml/min for the plasma and 1.3 ml/min for the CSF. The samples were frozen at -80°C and stored until analyzed. They were centrifuged for 5 min at 3,000 rpm. Samples with an internal standard [synthetic quinolone: 1-allyl-6-fluoro-1,4-dihydro-4-oxo-7(4-methyl-1-piperazinyl) quinoline 3-carboxylic acid] were precipitated by an equal volume of acetone. The mixture was vortexed for 1 min after centrifugation at 3,000 rpm for 5 min; 20 ,ul of the clear upper phase was then injected into the column.
The lower limit of sensitivity was 0.02 ,ug/ml, and the coefficient of variation on replicate determinations at 2.5 ,g of ciprofloxacin per ml was 2.5%. There was no interference with the ciprofloxacin assay when samples of plasma containing ampicillin, gentamicin, cefotaxime, and vancomycin at therapeutic concentrations were extracted and 20 ,ul was injected into the chromatographic column.
RESULTS
The mean peak levels in plasma were 5.5 ± 3.53 jig/ml during the acute stage of the disease and 4.42 + 2.93 ,ug/ml during the late stage. The mean trough levels were 0.27 ± 0.37 and 0.13 ± 0.09 jig/ml, respectively. However, trough levels were undetectable in seven cases. The concentrations of ciprofloxa in in CSF and in plasma obtained at the time of CSF drawing are shown in Table 2 . While mean plasma levels decreased from 1.59 ± 0.91 to 0.24 ± 0.13 p,g/ml between hours 1 and 8, there were no significant differences in mean CSF levels, which were 0.39 ± 0.22, 0.56 ± 0.39, 0.49 ± 0.20, and 0.35 ± 0.21 ,ug/ml, respectively, when the meninges were most inflamed. When the meningitis was considered to be cured, ciprofloxacin levels in CSF were 0.15 ± 0.04, 0.27 ± 0.09, 0.27 ± 0.16, and 0.15 ± 0.01 ,ug/ml at 60, 120, 240, and 480 min, respectively, after completion of the third infusion. The percentages of penetration, ex- Table 2 . The percentages in CSF of the peak plasma concentrations were 6.5 ± 3.1, 9.0 ± 6.2, 16.2 ± 15.3, and 10.2 5.5% during the acute stage and 4.5 ± 1.4, 5.5 ± 2.1, 9.9 7.7, and 4% during the late stage of the disease.
Ciprofloxacin levels obtained in ventricular fluid are shown in Fig. 1 (2) .
As the ciprofloxacin plasma half-life is about 4 h, the percentage of penetration into the CSF appeared to be inversely proportional to the plasma concentrations. Therefore the values of 56 and 159% observed at 4 and 8 h are not reliable. Since the concentrations of ciprofloxacin in CSF remained approximately the same during the 8-h period, the percentages in CSF of the peak plasma concentrations were more constant, ranging from 6.5 to 16%. In the late stage of meningitis the percentages of penetration were 14.5 and 22.5% during the first 2 h. In the 14 patients who were studied during both periods of the disease, the mean ratio of plasma concentrations in the acute to late stage was very near 1. In contrast, the mean ratio was 2.4 in CSF, suggesting that the diffusion of ciprofloxacin was 2.5 times higher during the acute stage. Ciprofloxacin diffuses in ventricular fluid, and detectable levels are found even 24 h after the last dose. An infant with P. aeruginosa ventriculitis was recently successfully treated with intravenous ciprofloxacin at a daily dose of 4 mg/kg. CSF ventricular concentrations ranged from 0.10 to 0.37 ,ug/ml (3). Another patient with P. aeruginosa meningitis was cured by ciprofloxacin associated with tobramycin, but the CSF concentrations of ciprofloxacin were not measured (4) .
From these data we suggest that (i) ciprofloxacin diffuses well into the CSF of patients with bacterial meningitis, (ii) this diffusion appears to persist (but to a lesser extent) beyond the point at which the meningitis is cured, and (iii) CSF concentrations exceed the MICS for most strains responsible for purulent meningitis. However, (iv) these levels may be close to the MICs for P. aeruginosa and staphylococci, and (v) further studies are needed to evaluate CSF bactericidal titers in patients treated with this agent. 
